Heptares Therapeutics Ltd

WELWYN GARDEN CITY, England - - Terms Include up to $200 million in Potential Fees and Milestones Plus Royalties Heptares Therapeutics Ltd, the drug discovery company focused on G-protein-coupled receptor (GPCR) targets, announced today that it has entered into an option agreement with the Novartis Option Fund under which Heptares will apply its proprietary StaR(TM) technology to generate novel drug leads against a nominated, unspecified GPCR target of interest to Novartis.